Complete Heart Block and HFpEF: Not a Direct Cause, But a Diagnostic Mimic
Complete heart block (CHB) does not cause heart failure with preserved ejection fraction (HFpEF); rather, it represents a distinct diagnostic entity that must be excluded when evaluating patients with suspected HFpEF, as CHB can mimic HFpEF symptoms but requires fundamentally different treatment (pacemaker therapy). 1
CHB as a HFpEF Mimic Requiring Exclusion
The 2023 ACC Expert Consensus explicitly categorizes high-degree atrioventricular block as a HFpEF mimic that must be identified during diagnostic evaluation, particularly in patients younger than 60 years. 1 This classification is critical because:
CHB can present with congestive symptoms (dyspnea, exercise intolerance, fatigue) that superficially resemble HFpEF but stem from bradycardia-induced low cardiac output rather than diastolic dysfunction. 1
The treatment paradigm is entirely different: CHB requires permanent pacemaker implantation, whereas HFpEF requires SGLT2 inhibitors, diuretics, and comorbidity management. 1, 2
Misdiagnosing CHB as HFpEF leads to inappropriate therapy and delays definitive treatment that can restore normal cardiac output and resolve symptoms. 1
Diagnostic Clues to Distinguish CHB from True HFpEF
When evaluating patients with suspected HFpEF, actively screen for CHB by looking for:
Marked bradycardia (heart rate typically <40-50 bpm at rest) that is inappropriate for the clinical context. 1
ECG findings showing complete dissociation between P waves and QRS complexes, with a slow ventricular escape rhythm. 1
Age <60 years should heighten suspicion, as this is specifically flagged as a diagnostic clue for CHB mimicking HFpEF. 1
Symptoms that improve dramatically with temporary pacing during diagnostic evaluation, confirming CHB as the primary problem rather than diastolic dysfunction. 1
The True Risk Factors for HFpEF Development
Actual HFpEF develops from a constellation of metabolic and cardiovascular comorbidities, not from conduction system disease:
Hypertension is the major risk factor for HFpEF development and is highly prevalent in those with established HFpEF. 3
Obesity is present in >80% of HFpEF patients, with excess intra-abdominal fat playing a pivotal role in the obese/metabolic HFpEF phenotype. 3
Diabetes affects 25-50% of HFpEF patients and confers adverse prognosis through neurohormonal activation, inflammation, and impaired skeletal muscle function. 3
Coronary artery disease is common in HFpEF and associates with greater deterioration in left ventricular systolic function and worse outcomes. 3
Aging and reduced physical activity are important contributors to HFpEF development. 3
Clinical Implications for Practice
When encountering a patient with dyspnea, exercise intolerance, and preserved ejection fraction:
Obtain a 12-lead ECG immediately to exclude CHB and other conduction abnormalities before labeling the patient as having HFpEF. 1, 2
If CHB is present, refer urgently for permanent pacemaker implantation rather than initiating HFpEF-directed medical therapy. 1
If CHB is absent and true HFpEF is confirmed, initiate SGLT2 inhibitors (empagliflozin or dapagliflozin) as first-line disease-modifying therapy, which reduce heart failure hospitalizations by approximately 20%. 2, 4, 5
Address underlying comorbidities including hypertension (target BP <130/80 mmHg), diabetes (preferentially with SGLT2 inhibitors), and obesity (through exercise training and weight loss). 2, 5
Common Pitfall to Avoid
The critical error is attributing congestive symptoms to HFpEF without first excluding CHB and other mimics. 1 This leads to:
Delayed pacemaker therapy in patients who could have immediate symptom resolution. 1
Inappropriate escalation of diuretics and other HFpEF medications that do not address the underlying bradycardia. 1
Missed opportunity for definitive treatment of a reversible cause of heart failure symptoms. 1
The diagnostic table from the ACC explicitly lists CHB alongside cardiac amyloidosis, hypertrophic cardiomyopathy, and other conditions that must be systematically excluded before confirming HFpEF diagnosis. 1